The first milestone: investing in InSilicoTrials

by | Aug 7, 2020

Levante Capital – the upcoming Italian VC Vehicle which focuses on expanding the reach of European Tech onto Asian Markets – is announcing today its first investment in InSilicoTrials, the cloud-based simulation healthcare company.

The € 350K ticket investment and – most importantly – Levante’s established extended Network in Asia will boost InsilicoTrials’ presence in the Healthcare Modeling & Simulation markets of China and South Korea initially.

The investment also kicks off Levante Capital’s investment strategy that regards Asia as an intrinsic frontline for South European Innovative Initiatives that are aiming to become true Global Champions, while turning their stakeholders into true Global Players as well.

Levante Capital – the upcoming Italian VC Vehicle which focuses on expanding the reach of European Tech onto Asian Markets – is announcing today its first investment in InSilicoTrials, the cloud-based simulation healthcare company.

The € 350K ticket investment and – most importantly – Levante’s established extended Network in Asia will boost InsilicoTrials’ presence in the Healthcare Modeling & Simulation markets of China and South Korea initially.

The investment also kicks off Levante Capital’s investment strategy that regards Asia as an intrinsic frontline for South European Innovative Initiatives that are aiming to become true Global Champions, while turning their stakeholders into true Global Players as well.

InSilicoTrials – as the name suggests – operates in the segment of clinical trials through computer simulations. Through the development of artificial models, researchers are able to assess the safety, efficacy, and risks of biomedical devices and pharmacological treatments with a view to their commercialization. While Simulation Modeling is an established approach in many industries, it is still a novelty when it comes to Pharma. That is the window of opportunity identified by Luca Emili and Roberta Bursi, Founder and Co-Founder of InSilicoTrials. It is a market made of 60K+ companies worldwide, growing constantly each year that will reach € 6.5 bn within 2025, ready to receive the company’s scalable and cloud-based solution that will democratize access to simulations in healthcare.

[READ THE FULL PRESS RELEASE HERE]

 

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *